Webinar
Platform Usage to Support Advanced Drug Modalities
Technology platforms not typically used for regulated bioanalysis are now utilized more frequently to support cell and gene therapy programs. Flow cytometry, ELISpot and quantitative…
ADA Assessment And Detection
Cell therapies are emerging and evolving as promising therapies for a variety of disease indications. The ability to detect anti-drug antibodies (ADA) is important for…
Strategies for Overcoming Drug Interference in Immunogenicity Assessment
Circulating drug can often interfere in the detection of anti-drug antibodies (ADAs). Therefore, it is imperative to develop bioanalytical assays that are able to reliably…
Total Bioanalytical Support for Antibody−Drug Conjugates (ADCs)
Antibody−drug conjugates (ADCs) typically contain a small molecule toxin (payload) linked to an antibody framework. The intent is to deliver the toxin in a targeted…
PK Assessment for Advanced Modalities (Cell & Gene Therapies)
The last few decades have seen a surge of new cell and gene therapies in drug development pipelines. The bioanalytical support for these complex modalities…
Assessing Cellular Immunogenicity via ELISpot
As therapeutic modalities have become more complex, such as cell and gene therapies, so too have the bioanalytical methods become more complex for characterizing these…
Total Antibody Assays for AAV-Based Gene Therapies – To Bridge or Not to Bridge
Assessing humoral immunogenicity is an interesting challenge for adeno-associated virus (AAV)-based gene therapies. While most people are concerned about how to deal with pre-existing antibodies…
Molecular Methods for Gene Therapies (GMP)
In association with Oxford Global, this webinar features an expert panel to discuss our work with potency assays for gene and cell therapy products. As…